No differences in HIF2α protein levels were observed between MSA variants defined according to clinical symptoms (MSA‐P vs MSA‐C, P > 0.9999; Supplementary Fig. 1A and Supplementary Table 2) or postmortem pathological subtype (MSA‐SND vs MSA‐OPCA, P > 0.9999; MSA‐SND vs MSA‐mixed, P > 0.9999; MSA‐OPCA vs MSA‐mixed, P > 0.9999; Supplementary Fig. 1B and Supplementary Table 3). This evidence concerns the gene EPAS1 and multiple system atrophy.